Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML.
The 2022 European LeukemiaNet (ELN22) genetic risk stratification for AML makes critical changes, including removal of FLT3-internal tandem duplications (ITD) allelic ratio and inclusion of mutations in myelodysplasia-related (MR) genes and in-frame bZIP CEBPA mutations. We evaluated the applicability of ELN22 in a uniformly treated younger AML cohort and explored refinements to improve risk prediction.
We retrospectively analyzed 473 adult patients with AML treated with intensive therapy. A combination of cytogenetics and next-generation sequencing was used to stratify patients into the ELN17 and ELN22 risk. In addition, we also evaluated leukemic stem cell (LSC) burden at diagnosis and postinduction measurable residual disease by multiparametric flow cytometry.
A total of 77 cases (16.3%) were reclassified from ELN17, primarily because of changes associated with FLT3-ITD, CEBPA, and MR gene mutations. As per ELN22, 56.7% of patients were classified as favorable, 28.3% intermediate, and 15.0% adverse risk. ELN22 adverse-risk patients had significantly inferior overall survival and relapse-free survival compared with intermediate- and favorable-risk patients. High LSC burden at diagnosis, presence of WT1 mutations, and DNMT3A-FLT3-ITD comutated NPM1 dichotomized the ELN22 intermediate-risk group.
We conclude that ELN22 is prognostically valid in intensively treated younger patients with AML. Incorporation of WT1 mutation status, triple-mutated NPM1, and LSC burden may improve risk stratification, particularly within the heterogeneous intermediate-risk category.
We retrospectively analyzed 473 adult patients with AML treated with intensive therapy. A combination of cytogenetics and next-generation sequencing was used to stratify patients into the ELN17 and ELN22 risk. In addition, we also evaluated leukemic stem cell (LSC) burden at diagnosis and postinduction measurable residual disease by multiparametric flow cytometry.
A total of 77 cases (16.3%) were reclassified from ELN17, primarily because of changes associated with FLT3-ITD, CEBPA, and MR gene mutations. As per ELN22, 56.7% of patients were classified as favorable, 28.3% intermediate, and 15.0% adverse risk. ELN22 adverse-risk patients had significantly inferior overall survival and relapse-free survival compared with intermediate- and favorable-risk patients. High LSC burden at diagnosis, presence of WT1 mutations, and DNMT3A-FLT3-ITD comutated NPM1 dichotomized the ELN22 intermediate-risk group.
We conclude that ELN22 is prognostically valid in intensively treated younger patients with AML. Incorporation of WT1 mutation status, triple-mutated NPM1, and LSC burden may improve risk stratification, particularly within the heterogeneous intermediate-risk category.
Authors
Mawalankar Mawalankar, Achrekar Achrekar, Biswas Biswas, Terse Terse, Joshi Joshi, Ugale Ugale, Bhanshe Bhanshe, Chaudhary Chaudhary, Kusurkar Kusurkar, Shahin Shahin, Gawde Gawde, Shetty Shetty, Jindal Jindal, Mirgh Mirgh, Shetty Shetty, Gokarn Gokarn, Punatar Punatar, Nayak Nayak, Jain Jain, Bagal Bagal, Sengar Sengar, Khattry Khattry, Rajpal Rajpal, Chatterjee Chatterjee, Tembhare Tembhare, Subramanian Subramanian, Patkar Patkar
View on Pubmed